In this randomized placebo-controlled intervention trial using the hyperoxia rat model for BPD, we were able to demonstrate for the first time that endothelin-1 receptor blockage with the dual ET-1 receptor antagonist macitentan prevented pulmonary vasculature rarefaction and right ventricular hypertrophy. This evidence concerns the gene EDNRA and bronchopulmonary dysplasia.